The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and β-glucuronidase in human colorectal tumours

British Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 122-129

  Tobin, Peter ^a   Clarke, Stephen ^b,d   Seale, J Paul ^a   Lee, Soon ^c   Solomon, Michael ^c   Aulds, Sally ^c   Crawford, Michael ^c   Gallagher, James ^c   Eyers, Tony ^c   Rivory, Laurent ^b  

^a University of Sydney   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d ANZAC Research Institute   (Australia)

Author keywords

CPT 11; Irinotecan; Metabolism; SN 38; Tumour

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BETA GLUCURONIDASE; CARBOXYLESTERASE; IRINOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL TUMOR; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; COLORECTAL NEOPLASMS; GLUCURONIDASE; HUMANS; HYDROXYQUINOLINES; NITROPHENOLS; TUMOR CELLS, CULTURED;

EID: 33746892240     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02477.x     Document Type: Article

References (25)

1. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
2. Haaz MC, Rivory LP, Riche C, Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN- 38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 257-62.
3. Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52: 1103-11.
4. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662-4.
5. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-91.
6. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-84.
7. Rivory LP, Riou JF, Haaz MC, Sable S, Vuihorgne M, Commercon A, Pond SM, Robert J. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56: 3689-94.
8. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998; 286: 578-83.
9. Ahmed F, Vyas V, Cornfield A, Goodin S, Ravikumar TS, Rubin EH, Gupta E. In vitro activation of irinotecan to SN-38 by human liver and intestine. Anticancer Res 1999; 19: 2067-71.
10. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R, Canal P. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999; 80: 364-70.
11. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-54.
12. Rivory LP, Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995; 36: 176-9.
13. Murdter TE, Sperker B, Kivisto KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, Kroemer HK. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res 1997; 57: 2440-5.
14. Sperker B, Werner U, Murdter TE, Tekkaya C, Fritz P, Wacke R, Adam U, Gerken M, Drewelow B, Kroemer HK. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 110-5.
15. Dodds HM, Tobin PJ, Stewart CF, Cheshire P, Hanna S, Houghton P, Rivory LP. The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther 2002; 303: 649-55.
16. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Specker B, Kroemer HK, Gesson JP, Koch M, Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998; 58: 1195-201.
17. Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br J Cancer 2001; 84: 550-7.
18. Lowry O, Rosebrough N, Farr A, Randall R Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
19. Warenius HM, Workman P, Bleehen NM, Response of a high-glucuronidase human tumour xenograft to aniline mustard. Br J Cancer 1982; 45: 27-34.
20. Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J Pharmacol Exp Ther 1997; 282: 909-19.
21. Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity. Biochem Pharmacol 1993; 46: 1953-8.
22. Miyauchi S, Sugiyama Y, Iga T, Hanano M The conjugative metabolism of 4-methylumbelliferone and deconjugation to the parent drug examined by isolated perfused liver and in vitro liver homogenate of rats. Chem Pharm Bull (Tokyo) 1989; 37: 475-80.
23. Sperker B, Tomkiewicz C, Burk O, Barouki R, Kroemer HK. Regulation of human beta-glucuronidase by A23187 and thapsigargin in the hepatoma cell line HepG2. Mol Pharmacol 2001; 59: 177-82.
24. Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999; 17: 685-96.
25. Kaneda N, Kurita A, Hosokawa Y, Yokokura T, Awazu S. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats. Cancer Res 1997; 57: 5305-8.